摘要
目的探讨结直肠癌患者中KRAS和BRAF基因突变与患者预后的关系。方法采用二代测序(NGS)技术检测2017年1月至2020年1月在咸宁市中心医院病理科存档的60例结直肠癌患者的组织标本中的KRAS和BRAF基因突变情况,分析两者基因突变与患者临床病理特征的相关性及对预后的影响,并探讨患者OS的影响因素。结果60例结直肠癌患者的KRAS基因突变率为41.7%(25/60),以第2外显子突变为主,BRAF基因突变率为8.3%(5/60),全部为15外显子突变,未见两者共突变。KRAS基因突变与患者病理分型及N分期明显相关,BRAF基因突变主要与病理分型及远处转移有关。KRAS基因突变患者疾病控制率明显低于野生型患者。患者的病理分型、T分期、N分期、BRAF突变是影响患者OS的独立影响因素。BRAF突变患者的OS及PFS均明显低于野生型患者,KRAS突变对患者的OS及PFS无影响。结论在结直肠癌中KRAS突变率较高,与患者的分化程度及淋巴结转移关系密切;BARF突变率较低,与分化程度、远处转移及不良预后相关。
Objective To investigate the relationship between KRAS and BRAF gene mutations and prog⁃nosis in colorectal cancer patients.Methods From January 2017 to January 2020,tissue samples from 60 patients with colorectal cancer submitted at the pathology department of our hospital were examined for KRAS and BRAF gene mutations using next⁃generation sequencing(NGS)technology.Analysis was done on the relationship between patient clinic pathological features and KRAS and BRAF gene mutations,as well as how these factors affected prog⁃nosis.The COX regression model was employed to examine the variables affecting OS in CRC patients.Results The KRAS gene mutation rate of 60 colorectal cancer patients was 41.7%(25/60),t with the second exon mutation being the most common,and the BRAF gene mutation rate was 8.3%(5/60),all of which were exon 15 mutations with no co⁃mutation found.KRAS gene mutation is significantly related to pathological type and N stage,while BRAF gene mutation is mainly related to pathological type and distant metastasis.The disease control rate of KRAS mutation patients was significantly lower than that of wild⁃type patients.Pathological type,T stage,N stage,and BRAF mutation are all independent factors that influence OS.BRAF mutation patients had significantly lower OS and PFS than wild⁃type patients,while KRAS mutation had no effect on OS and PFS.Conclusion KRAS mu⁃tation rates were high in colorectal cancer,and they were closely related to patients′degree of differentiation and lymph node metastasis.BARF mutation rates was low,which was related to the degree of differentiation,distant me⁃tastasis,and poor prognosis.
作者
司马学琴
苏延停
曾智
SIMA Xueqin;SU Yanting;ZENG Zhi(Basic Medical College,Hubei University of Science and Technology,Xianning 437100,China;不详)
出处
《实用医学杂志》
CAS
北大核心
2022年第21期2670-2675,共6页
The Journal of Practical Medicine
基金
国家自然科学基金(编号:32000906)。
关键词
二代测序
结直肠癌
KRAS
BRAF
突变
预后
next generation sequencing
colorectal cancer
KRAS
BRAF
mutation
prognosis
